Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lifeline for myeloma patients: continued access to promising drug

NCT ID NCT06057402

Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This study offers ongoing access to the drug elranatamab for people with multiple myeloma who were already benefiting from it in earlier Pfizer studies. The goal is to keep providing the treatment while monitoring for any side effects. About 80 participants will take part, and the study is currently recruiting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2023

Expected to finish

Feb 2032

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants must agree to follow the reproductive criteria as outlined in the protocol * Participants have completed a qualifying Parent Study, were still receiving elranatamab when the Parent Study terminated or completed, and are deriving clinical benefit from elranatamab (as determined by the investigator). Exclusion Criteria: * Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study. * Participants not previously enrolled or who have discontinued study treatment in a Parent Study are ineligible for participation in this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple myeloma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple myeloma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    31 sites in 7 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Arthur J.E. Child Comprehensive Cancer Centre

    RECRUITING

    Calgary, Alberta, T2N 5GN, Canada

  • Clinica Universidad de Navarra

    RECRUITING

    Pamplona, Navarre, 31008, Spain

  • Cross Cancer Institute

    RECRUITING

    Edmonton, Alberta, T6G 1Z2, Canada

  • Epworth Freemasons

    RECRUITING

    Melbourne, Victoria, 3002, Australia

  • Epworth Hospital

    RECRUITING

    Richmond, Victoria, 3121, Australia

  • Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion)

    RECRUITING

    Detroit, Michigan, 48202, United States

  • Hospital Universitario Doctor Peset

    RECRUITING

    Valencia, València, 46017, Spain

  • Japanese Red Cross Medical Center

    RECRUITING

    Shibuya-ku, Tokyo, 150-8935, Japan

  • Longs Peak Hospital

    RECRUITING

    Longmont, Colorado, 80504, United States

  • McGill University Health Centre

    RECRUITING

    Montreal, Quebec, H4A 3J1, Canada

  • National Taiwan University Hospital

    RECRUITING

    Taipei, 10002, Taiwan

  • Peking University Third Hospital

    ACTIVE_NOT_RECRUITING

    Beijing, Beijing Municipality, 100191, China

  • Shandong Provincial Hospital

    RECRUITING

    Jinan, Shandong, 250021, China

  • Slade Pharmacy

    RECRUITING

    Richmond, Victoria, 3121, Australia

  • St. David's South Austin Medical Center

    RECRUITING

    Austin, Texas, 78704, United States

  • Sun Yat-sen University Cancer Center

    ACTIVE_NOT_RECRUITING

    Guangzhou, Guangdong, 510555, China

  • Sylvester Comprehensive Cancer Center

    RECRUITING

    Miami, Florida, 33136, United States

  • Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical Center

    RECRUITING

    Coral Gables, Florida, 33146, United States

  • Taipei Veterans General Hospital

    RECRUITING

    Taipei, 11217, Taiwan

  • The first Affiliated Hospital, Zhejiang University School of Medicine

    RECRUITING

    Hangzhou, Zhejiang, 310003, China

  • UC Irvine Health

    RECRUITING

    Orange, California, 92612, United States

  • UCHealth - Medical Center of the Rockies

    RECRUITING

    Loveland, Colorado, 80538, United States

  • UCHealth Greeley Hospital

    RECRUITING

    Greeley, Colorado, 80634, United States

  • UCHealth Harmony

    RECRUITING

    Fort Collins, Colorado, 80528, United States

  • UCHealth Longs Peak Medical Center

    RECRUITING

    Longmont, Colorado, 80504, United States

  • UCHealth Poudre Valley Hospital

    RECRUITING

    Fort Collins, Colorado, 80524, United States

  • UCI Health

    RECRUITING

    Orange, California, 92868, United States

  • UCI Health - Irvine Infusion Pharmacy ACC

    RECRUITING

    Irvine, California, 92612, United States

  • University Hospital,Kyoto Prefectural University of Medicine

    RECRUITING

    Kyoto, 602-8566, Japan

  • University of Miami Hospital and Clinics

    RECRUITING

    Miami, Florida, 33136, United States

  • University of Miami Hospital and Clinics - Griffin Cancer Research Building

    RECRUITING

    Miami, Florida, 33136, United States

  • University of Miami Hospital and Clinics Deerfield Beach

    RECRUITING

    Deerfield Beach, Florida, 33442, United States

  • University of Michigan

    RECRUITING

    Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.